**Internal review charge questions - February 2018**

## AOP Information

* AOP title: Histone deacetylase inhibition leading to testicular toxicity
* Author: Shihori Tanabe, Akihiko Hirose, Takashi Yamada ([t-yamada@nihs.go.jp](mailto:t-yamada@nihs.go.jp))
* Associated wiki page: <https://aopwiki.org/aops/212>

## Reviewers

**Primary Reviewer (PR):** Name: Dan Villeneuve; OECD Country/Org.: United States;

Email: [Villeneuve.Dan@epa.gov](mailto:Villeneuve.Dan@epa.gov)

**Secondary reviewer 1 (SR1)** Name: Jason Obrien; OECD Country/Org.: Canada;

Email: [jason.obrien@canada.ca](mailto:jason.obrien@canada.ca)

**Secondary reviewer 2 (SR2)** Name: Gladys Ouedraogo; OECD Country/Org.: BIAC;

Email: [GOUEDRAOGO@rd.loreal.com](mailto:GOUEDRAOGO@rd.loreal.com)

#### Date review completed:

## Review

**Section 1:**

|  |
| --- |
| **AOP identifier/Title**  *Does the name of the AOP follow the right convention (MIE or first KE leading to AO)?*  *Does the name of the AOP reflect its content/domain?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 2:**

|  |
| --- |
| **Authors**  *Is it clear who the authors/developers of the AOP are?*  *Contact information for one or more corresponding author(s) should be included.* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 3:**

|  |
| --- |
| **Date of updating**  *Reviewer should indicate the date stamp on the PDF snapshot under review.* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 4:**

|  |
| --- |
| **Abstract**  *Does the abstract concisely describe the main content of the AOP?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 5:**

|  |
| --- |
| **Molecular Initiating Event**  *Is a MIE described? If yes, then:*  *Is the MIE description clear and is it biologically plausible?*  *Is the MIE described in a way that allows its use in other AOPs?*  *Are measurement/prediction methods specified and adequately described/referenced?*  *Is the biological context (inc. taxonomic applicability/relevance, level of biological organisation) specified and explained sufficiently?*  *Have chemical initiators (prototypical chemicals or chemical features) been identified?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

|  |
| --- |
| Key Events *Are the KE descriptions clear on how the events work and are they biologically plausible?*  *Are the KEs described in a way that allows their reuse in other AOPs?*  *Are measurement methods specified and adequately described/referenced?*  *Is the biological context (inc. taxonomic applicability/relevance, level of biological organisation) specified and explained sufficiently?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

|  |
| --- |
| **Adverse Outcome**  *Is an AO described? If yes, then:*  *Is the AO description clear and is it biologically plausible?*  *Is the AO described in a way that allows its use in other AOPs?*  *Are measurement methods specified and adequately described/referenced?*  *Is the biological context (inc. taxonomic applicability/relevance, level of biological organisation) specified and explained sufficiently?*  *Has the regulatory relevance of the AO been described?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 6:**

|  |
| --- |
| **Key Event Relationships**  *Are the KERs well described and in a way that allows their use in other AOPs?*  *Are the KERs biologically plausible and is there sufficient evidence presented?*  *Is the level of empirical support adequately described in accordance with the OECD AOP Handbook?*  *Are inconsistencies, uncertainties and level of confidence adequately described?*  *Is the quantitative understanding of the KER described?"*  *[refer to Tables 2 & 3 in the handbook]* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 7:**

|  |
| --- |
| **Overall Assessment of the AOP**  *Is the domain of applicability of the AOP defined appropriately?*  *Is the level of support for essentiality of the KEs adequately described and assessed?*  *Has the degree of quantitative understanding of KERs been assessed properly?*  *Has consideration been given to the overall weight of evidence for the AOP?*  *Are the calls on Overall WoE and Quantitative Understanding supported?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**Section 8:**

|  |
| --- |
| **Potential application of the AOP (optional):**  *Is any context provided as regards the reason for development or the intended use?* |

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |

**General Observations and Conclusions of the Reviewer**

|  |
| --- |
| **Reviewers' responses and comments**  **PR:**  **SR1:**  **SR2:** |

|  |
| --- |
| **Author response:** |